Evolving Early Breast Cancer Care: Sustained Impact of CDK4/6 Inhibitors Across a Broader Stage II and Stage III HR+/HER2-Population
洪進昇
趙祖怡
701B
10:00 - 10:10
Coffee Break
701B
10:10 - 10:50
Whole-genome landscapes of 1364 breast cancers
Yeon Hee Park
張金堅
701B
10:50 - 11:30
Navigating Luminal Heterogeneity: Proteogenomic Subtyping for Targeted Treatment Strategies in Breast Cancer
陳玉如
侯明鋒
701B
11:30 - 11:40
Real-World Effectiveness and Safety of Sacituzumab Govitecan in Taiwanese Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter Retrospective Study
周旭桓
陳訓徹
701B
11:40 - 11:50
Real-World Data on Treatment Efficacy in Patients With Residual HER2-Positive Early Breast Cancer
洪志強
俞志誠
701B
11:50 - 12:00
Real-World Efficacy and Safety of Oral Combination Metronomic Chemotherapy in Metastatic Breast Cancer -A Taiwanese Multicenter Study as First-Line Chemotherapy in the Post-CDK4/6 Inhibitor Setting